December 1, 2022
Meiji Seika Pharma said on November 30 that it took over the Japanese marketing authorization (MA) for the cancer drug Hiyasta (tucidinostat) from HUYA Japan, effective the same day. An oral histone deacetylase (HDAC) inhibitor, Hiyasta was approved in Japan...read more